Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a…
Search
Tag: Nasdaq:JSPR
